Accendra Health (NYSE:ACH) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Accendra Health (NYSE:ACH) announced its earnings results on Monday. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.06), FiscalAI reports. The company had revenue of $613.23 million for the quarter. Accendra Health had a negative net margin of 11.41% and a negative return on equity of 4.24%.

Accendra Health Stock Performance

Shares of Accendra Health stock opened at $1.24 on Wednesday. Accendra Health has a 1 year low of $1.20 and a 1 year high of $5.85. The stock has a market cap of $94.96 million, a P/E ratio of -0.32, a P/E/G ratio of 2.16 and a beta of 1.58. The business has a 50-day simple moving average of $3.13.

Hedge Funds Weigh In On Accendra Health

A number of large investors have recently made changes to their positions in the business. Keybank National Association OH purchased a new stake in shares of Accendra Health in the first quarter worth approximately $46,000. Strs Ohio acquired a new position in Accendra Health in the 1st quarter valued at approximately $413,000. Abel Hall LLC acquired a new position in Accendra Health in the 1st quarter valued at approximately $44,000. Hsbc Holdings PLC purchased a new stake in Accendra Health in the 1st quarter worth approximately $34,000. Finally, Bank of New York Mellon Corp purchased a new stake in Accendra Health in the 1st quarter worth approximately $592,000.

Analyst Ratings Changes

A number of analysts have commented on ACH shares. Weiss Ratings lowered shares of Accendra Health from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 6th. Citigroup lowered shares of Accendra Health from a “buy” rating to a “neutral” rating and cut their price target for the company from $4.50 to $1.50 in a report on Monday. UBS Group upped their price target on shares of Accendra Health from $3.00 to $4.50 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Robert W. Baird set a $1.50 price objective on shares of Accendra Health and gave the stock a “neutral” rating in a research note on Tuesday. Finally, Zacks Research upgraded shares of Accendra Health from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 21st. Four research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $2.50.

About Accendra Health

Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services.